The effects of canthaxanthin on the photocutaneous manifestations of porphyria.
An open trial with canthaxanthin, a photoprotective agent, was carried out on 7 patients with erythrohepatic protoporphyria (EHP), 5 patients with variegate porphyria (VP), and 2 patients with symptomatic porphyria (SP). In 4 of the 7 patients with EHP, sun tolerance was significantly but only moderately increased. In 2 children sun tolerance was greatly increased. Only 2 of the 5 patients with VP and 1 of the 2 patients with SP showed any improvement.
D000293:Adolescent; D000328:Adult; D002338:Carotenoids / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003306:Coproporphyrins / Q000032:analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010787:Photosensitivity Disorders / Q000188:drug therapy*; D011164:Porphyrias / Q000188:drug therapy*; D011524:Protoporphyrins / Q000032:analysis; D014578:Uroporphyrins / Q000032:analysis
D003306:Coproporphyrins; D011524:Protoporphyrins; D014578:Uroporphyrins; D002338:Carotenoids